Biopharmx Corp (NYSE:BPMX) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus price target of $2.78 for the company and are anticipating that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given Biopharmx Corp an industry rank of 122 out of 265 based on the ratings given to related companies.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/11/06/zacks-analysts-set-2-78-price-target-for-biopharmx-corp-bpmx.html.
Shares of Biopharmx Corp (NYSE:BPMX) remained flat at $$0.17 on Monday. The stock had a trading volume of 538,702 shares, compared to its average volume of 1,450,000. Biopharmx Corp has a fifty-two week low of $0.16 and a fifty-two week high of $0.90.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Biopharmx Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biopharmx Corp and related companies.